[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584477":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":67,"collaborators":10,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":10,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":10,"enrollmentInfo":78,"targetDuration":81,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"ADVANCED MARKER DISCOVERY S.L.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cancer or Gastrointestinal Disease",null,"A different types of cancer and gastrointestinal disease will be included in the cohort such as breast cancer, bladder cancer, IBDs, Leukemia and Lung cancer.",[13],"Diagnostic Test: blood sampling",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","blood sampling","Patients will donate a blood sample for molecular analysis of molecular biomarkers in plasma, which being the only procedure in the study.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Marta Jimenez","CONTACT","+34637899149","mjimenez@amadix.com",[27,40,44,53,61],{"facility":28,"status":29,"city":30,"state":31,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":10},"Hospitales HM de Malaga","RECRUITING","Málaga","Andalusia","Spain","ES",{"type":35,"coordinates":36},"Point",[37,38],-4.42034,36.72016,{"lat":38,"lon":37},{"facility":41,"status":29,"city":42,"state":43,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Hospital Centro Médico Asturias","Oviedo","Cantabria",{"facility":45,"status":29,"city":46,"state":47,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":48,"geoPoint":52,"contacts":10},"Hospital Universitario de Ourense","Ourense","Galicia",{"type":35,"coordinates":49},[50,51],-7.86407,42.33669,{"lat":51,"lon":50},{"facility":54,"status":29,"city":55,"state":55,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":56,"geoPoint":60,"contacts":10},"Hospital Universitario HM Sanchinarro","Madrid",{"type":35,"coordinates":57},[58,59],-3.70256,40.4165,{"lat":59,"lon":58},{"facility":62,"status":63,"city":55,"state":55,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":64,"geoPoint":66,"contacts":10},"MD Anderson Cancer Centre","ACTIVE_NOT_RECRUITING",{"type":35,"coordinates":65},[58,59],{"lat":59,"lon":58},{"type":68,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100584477","observational-cross-reactivity-study-for-colorectal-cancer-diagnosis-100584477",false,"NCT06889844","Observational Cross-reactivity Study for Colorectal Cancer Diagnosis","Observational Cross-reactivity Study to Evaluate the Specificity of a Blood Test for Colorectal Cancer Diagnosis Based on Molecular Markers and Risk Factors Identified With Artificial Intelligence Tools","Inclusion Criteria:\n\n* Patients older than 18 years of age at the time of blood sample collection.\n* Subjects must be able to understand the information provided on the participant information sheet, must consent to participate in the study, and must sign the informed consent form.\n* Patients diagnosed with only one type of cancer (no colorectal cacner) or gastrointestinal disease.\n\nExclusion Criteria:\n\n* Patients who have received previous chemotherapy or radiotherapy.\n* In case of diagnosis of a tumor: patients who have undergone total or partial surgical resection of the tumor.\n* Patients with a personal history of advanced or non-advanced colorectal adenoma, serrated lesions, colorectal cancer, familial adenomatous polyposis or Lynch syndrome.\n* Patients without appropriate staging or diagnosis.\n* Patients with hemolyzed plasma.","ALL","18 Years",{"count":79,"type":80},250,"ESTIMATED","1 Day","OBSERVATIONAL","The objective of this observational study is to evaluate the false positive rate of the blood test based on molecular biomarkers and risk factors. A total of 250 patients diagnosed with various cancers and gastrointestinal diseases will be enrolled. The main question to be answered is\n\nDoes the blood test have a low false positive rate in the main study population?\n\nParticipants will donate a blood sample as part of their regular medical care for cancer diagnosis and give the consent to know their clinical risk factors.",[85],"Colorectal Cancer","2025-09-29",{"date":88,"type":89},"2025-10-01","ACTUAL",{"date":91,"type":89},"2023-04-17",{"date":93,"type":80},"2025-12",{"name":5,"class":6},5]